Can osteoprotegerin be used to identify the presence and severity of coronary artery disease in different clinical settings?

Atherosclerosis

Volumn 236, Issue 2, 2014, Pages 230-236

  Hosbond, Susanne Elisabeth ^a   Diederichsen, Axel Cosmus Pyndt ^a   Saaby, Lotte ^a   Rasmussen, Lars Melholt ^a   Lambrechtsen, Jess ^a   Munkholm, Henrik ^b   Sand, Niels Peter Rønnow ^c,d   Gerke, Oke ^a,d   Poulsen, Tina Svenstrup ^a   Mickley, Hans ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b LILLEBAELT HOSPITAL   (Denmark)

^c Centre for Individualized Medicine of Arterial Diseases Odense University Hospital ^*  (Denmark)

^d UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Coronary artery disease; Coronary calcification; Diagnostic utility; Osteoprotegerin

Indexed keywords

OSTEOPROTEGERIN; BIOLOGICAL MARKER; CALCIUM; TNFRSF11B PROTEIN, HUMAN;

ACUTE HEART INFARCTION; ADULT; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ARTICLE; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; SENSITIVITY AND SPECIFICITY; AREA UNDER THE CURVE; BLOOD; CALCINOSIS; CLINICAL TRIAL; COMORBIDITY; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; CORONARY DISEASE; DIABETES MELLITUS; HYPERLIPIDEMIAS; HYPERTENSION; MIDDLE AGED; MYOCARDIAL INFARCTION; RADIOGRAPHY; RECEIVER OPERATING CHARACTERISTIC; SEVERITY OF ILLNESS INDEX; SMOKING;

ANGINA PECTORIS; AREA UNDER CURVE; BIOMARKERS; CALCINOSIS; CALCIUM; COMORBIDITY; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY DISEASE; DIABETES MELLITUS; FEMALE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; OSTEOPROTEGERIN; ROC CURVE; SAMPLING STUDIES; SEVERITY OF ILLNESS INDEX; SMOKING; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84907078392     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.07.013     Document Type: Article

References (50)

1. Brown S.A., Rosen C.J. Osteoporosis. Med Clin North Am 2003 Sep, 87(5):1039-1063.
2. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Luthy R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997 Apr 18, 89(2):309-319.
3. Dhore C.R., Cleutjens J.P., Lutgens E., Cleutjens K.B., Geusens P.P., Kitslaar P.J., et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2001 Dec, 21(12):1998-2003.
4. Hofbauer L.C., Shui C., Riggs B.L., Dunstan C.R., Spelsberg T.C., O'Brien T., et al. Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. Biochem Biophys Res Commun 2001 Jan 12, 280(1):334-339.
5. Olesen P., Ledet T., Rasmussen L.M. Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-alpha. Diabetologia 2005 Mar, 48(3):561-568.
6. Collin-Osdoby P., Rothe L., Anderson F., Nelson M., Maloney W., Osdoby P. Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem 2001 Jun 8, 276(23):20659-20672.
7. Nybo M., Rasmussen L.M. The capability of plasma osteoprotegerin as a predictor of cardiovascular disease: a systematic literature review. Eur J Endocrinol 2008 Nov, 159(5):603-608.
8. Schoppet M., Preissner K.T., Hofbauer L.C. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol 2002 Apr 1, 22(4):549-553.
9. Hofbauer L.C., Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004 Jul 28, 292(4):490-495.
10. Crisafulli A., Micari A., Altavilla D., Saporito F., Sardella A., Passaniti M., et al. Serum levels of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction. Clin Sci (Lond) 2005 Oct, 109(4):389-395.
11. Jono S., Ikari Y., Shioi A., Mori K., Miki T., Hara K., et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002 Sep 3, 106(10):1192-1194.
12. Palazzuoli A., Rizzello V., Calabro A., Gallotta M., Martini G., Quatrini I., et al. Osteoprotegerin and B-type natriuretic peptide in non-ST elevation acute coronary syndromes: relation to coronary artery narrowing and plaques number. Clin Chim Acta 2008 May, 391(1-2):74-79.
13. Ren M.Y., Sui S.J., Zhang Y., Xu F.Y., Xu X.Q., Zhao J.J., et al. Increased plasma osteoprotegerin levels are associated with the presence and severity of acute coronary syndrome. Acta Cardiol 2008 Oct, 63(5):615-622.
14. Schoppet M., Sattler A.M., Schaefer J.R., Herzum M., Maisch B., Hofbauer L.C. Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab 2003 Mar, 88(3):1024-1028.
15. Hosbond S.E., Poulsen T.S., Diederichsen A.C., Nybo M., Rasmussen L.M., Mickley H. Osteoprotegerin as a marker of atherosclerosis: a systematic update. Scand Cardiovasc J 2012 Aug, 46(4):203-211.
16. Mogelvang R., Pedersen S.H., Flyvbjerg A., Bjerre M., Iversen A.Z., Galatius S., et al. Comparison of osteoprotegerin to traditional atherosclerotic risk factors and high-sensitivity C-reactive protein for diagnosis of atherosclerosis. Am J Cardiol 2012 Feb 15, 109(4):515-520.
17. Ciccone M.M., Scicchitano P., Gesualdo M., Zito A., Carbonara R., Locorotondo M., et al. Serum osteoprotegerin and carotid intima-media thickness in acute/chronic coronary artery diseases. J Cardiovasc Med (Hagerstown) 2013 Jan, 14(1):43-48.
18. Jensen J.K., Ueland T., Atar D., Gullestad L., Mickley H., Aukrust P., et al. Osteoprotegerin concentrations and prognosis in acute ischaemic stroke. J Intern Med 2010 Apr, 267(4):410-417.
19. Jono S., Otsuki S., Higashikuni Y., Shioi A., Mori K., Hara K., et al. Serum osteoprotegerin levels and long-term prognosis in subjects with stable coronary artery disease. J Thromb Haemost 2010 Jun, 8(6):1170-1175.
20. Omland T., Ueland T., Jansson A.M., Persson A., Karlsson T., Smith C., et al. Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. J Am Coll Cardiol 2008 Feb 12, 51(6):627-633.
21. Vik A., Mathiesen E.B., Noto A.T., Sveinbjornsson B., Brox J., Hansen J.B. Serum osteoprotegerin is inversely associated with carotid plaque echogenicity in humans. Atherosclerosis 2007 Mar, 191(1):128-134.
22. Vik A., Mathiesen E.B., Johnsen S.H., Brox J., Wilsgaard T., Njolstad I., et al. Serum osteoprotegerin, sRANKL and carotid plaque formation and growth in a general population-the Tromso study. J Thromb Haemost 2010 May, 8(5):898-905.
23. Agatston A.S., Janowitz W.R., Hildner F.J., Zusmer N.R., Viamonte M., Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990 Mar 15, 15(4):827-832.
24. Agatston A.S., Janowitz W.R., Kaplan G., Gasso J., Hildner F., Viamonte M. Ultrafast computed tomography-detected coronary calcium reflects the angiographic extent of coronary arterial atherosclerosis. Am J Cardiol 1994 Dec 15, 74(12):1272-1274.
25. Yeboah J., McClelland R.L., Polonsky T.S., Burke G.L., Sibley C.T., O'Leary D., et al. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA 2012 Aug 22, 308(8):788-795.
26. Erbel R., Mohlenkamp S., Moebus S., Schmermund A., Lehmann N., Stang A., et al. Coronary risk stratification, discrimination, and reclassification improvement based on quantification of subclinical coronary atherosclerosis: the Heinz Nixdorf Recall study. J Am Coll Cardiol 2010 Oct 19, 56(17):1397-1406.
27. Polonsky T.S., McClelland R.L., Jorgensen N.W., Bild D.E., Burke G.L., Guerci A.D., et al. Coronary artery calcium score and risk classification for coronary heart disease prediction. JAMA 2010 Apr 28, 303(16):1610-1616.
28. Christensen H.W., Haghfelt T., Vach W., Johansen A., Hoilund-Carlsen P.F. Observer reproducibility and validity of systems for clinical classification of angina pectoris: comparison with radionuclide imaging and coronary angiography. Clin Physiol Funct Imaging 2006 Jan, 26(1):26-31.
29. Diederichsen A.C., Sand N.P., Norgaard B., Lambrechtsen J., Jensen J.M., Munkholm H., et al. Discrepancy between coronary artery calcium score and HeartScore in middle-aged Danes: the DanRisk study. Eur J Prev Cardiol 2012 Jun, 19(3):558-564.
30. Diamond G.A. A clinically relevant classification of chest discomfort. J Am Coll Cardiol 1983 Feb, 1(2 Pt 1):574-575.
31. Campeau L. Letter: Grading of angina pectoris. Circulation 1976 Sep, 54(3):522-523.
32. Saaby L., Poulsen T.S., Hosbond S., Larsen T.B., Pyndt Diederichsen A.C., Hallas J., et al. Classification of myocardial infarction: frequency and features of type 2 myocardial infarction. Am J Med 2013 Sep, 126(9):789-797.
33. Thygesen K., Alpert J.S., White H.D. Universal definition of myocardial infarction. Eur Heart J 2007 Oct, 28(20):2525-2538.
34. Newcombe R.G., Altman D.G. Proportions and their differences. Statistics with confidence 2000, BMJ books, Bristol. 2nd ed. D.G. Altman, D. Machin, T.N. Bryant, M.J. Gardner (Eds.).
35. Zhou X.H., Obuchowski N.A., McClish D.K. Statistical methods in diagnostic medicine 2011, Blackwell-Wiley, New York. 2nd ed.
36. Collin-Osdoby P. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res 2004 Nov 26, 95(11):1046-1057.
37. Mesquita M., Demulder A., Damry N., Melot C., Wittersheim E., Willems D., et al. Plasma osteoprotegerin is an independent risk factor for mortality and an early biomarker of coronary vascular calcification in chronic kidney disease. Clin Chem Lab Med 2009, 47(3):339-346.
38. Mesquita M., Demulder A., Wolff F., Melot C., Damry N., Dratwa M., et al. Osteoprotegerin and progression of coronary and aortic calcifications in chronic kidney disease. Transplant Proc 2010 Nov, 42(9):3444-3449.
39. Morena M., Dupuy A.M., Jaussent I., Vernhet H., Gahide G., Klouche K., et al. A cut-off value of plasma osteoprotegerin level may predict the presence of coronary artery calcifications in chronic kidney disease patients. Nephrol Dial Transplant 2009 Nov, 24(11):3389-3397.
40. Morena M., Jaussent I., Halkovich A., Dupuy A.M., Bargnoux A.S., Chenine L., et al. Bone biomarkers help grading severity of coronary calcifications in non dialysis chronic kidney disease patients. PLoS One 2012, 7(5):e36175.
41. Anand D.V., Lahiri A., Lim E., Hopkins D., Corder R. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J Am Coll Cardiol 2006 May 2, 47(9):1850-1857.
42. Jung C.H., Lee W.Y., Kim S.Y., Jung J.H., Rhee E.J., Park C.Y., et al. The relationship between coronary artery calcification score, plasma osteoprotegerin level and arterial stiffness in asymptomatic type 2 DM. Acta Diabetol 2010 Dec, 47(Suppl 1):145-152.
43. Abedin M., Omland T., Ueland T., Khera A., Aukrust P., Murphy S.A., et al. Relation of osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart Study). Am J Cardiol 2007 Feb 15, 99(4):513-518.
44. Pedersen E.R., Ueland T., Seifert R., Aukrust P., Schartum-Hansen H., Ebbing M., et al. Serum osteoprotegerin levels and long-term prognosis in patients with stable angina pectoris. Atherosclerosis 2010 Oct, 212(2):644-649.
45. Kudlacek S., Schneider B., Woloszczuk W., Pietschmann P., Willvonseder R. Serum levels of osteoprotegerin increase with age in a healthy adult population. Bone 2003 Jun, 32(6):681-686.
46. Vik A., Brodin E., Sveinbjornsson B., Hansen J.B. Heparin induces mobilization of osteoprotegerin into the circulation. Thromb Haemost 2007 Jul, 98(1):148-154.
47. Cosin-Sales J., Kaski J.C., Christiansen M., Kaminski P., Oxvig C., Overgaard M.T., et al. Relationship among pregnancy associated plasma protein-A levels, clinical characteristics, and coronary artery disease extent in patients with chronic stable angina pectoris. Eur Heart J 2005 Oct, 26(20):2093-2098.
48. Inoue T., Eguchi Y., Matsumoto T., Kijima Y., Kato Y., Ozaki Y., et al. Lipocalin-type prostaglandin D synthase is a powerful biomarker for severity of stable coronary artery disease. Atherosclerosis 2008 Dec, 201(2):385-391.
49. Kastrup J. Can YKL-40 be a new inflammatory biomarker in cardiovascular disease?. Immunobiology 2012 May, 217(5):483-491.
50. Mathiasen A.B., Harutyunyan M.J., Jorgensen E., Helqvist S., Ripa R., Gotze J.P., et al. Plasma YKL-40 in relation to the degree of coronary artery disease in patients with stable ischemic heart disease. Scand J Clin Lab Invest 2011 Sep, 71(5):439-447.